

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> ( Not for submission under 37 CFR 1.99)	Application Number		10569583	
	Filing Date		2006-02-23	
	First Named Inventor	Neil Gallagher		
	Art Unit	1654		
	Examiner Name	Julie Ha		
	Attorney Docket Number	101213-1P US		

U.S.PATENTS							Remove
Examiner Initial*	Cite No	Patent Number	Kind Code <sup>1</sup>	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	
	1						

If you wish to add additional U.S. Patent citation information please click the Add button.

Add

U.S.PATENT APPLICATION PUBLICATIONS							Remove
Examiner Initial*	Cite No	Publication Number	Kind Code <sup>1</sup>	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	
	1						

If you wish to add additional U.S. Published Application citation information please click the Add button.

Add

FOREIGN PATENT DOCUMENTS								Remove
Examiner Initial*	Cite No	Foreign Document Number <sup>3</sup>	Country Code <sup>2</sup> i	Kind Code <sup>4</sup>	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	T <sup>5</sup>
	1							<input type="checkbox"/>

If you wish to add additional Foreign Patent Document citation information please click the Add button

Add

NON-PATENT LITERATURE DOCUMENTS				Remove
Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>5</sup>	

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
( Not for submission under 37 CFR 1.99)

Application Number	10569583
Filing Date	2006-02-23
First Named Inventor	Neil Gallagher
Art Unit	1654
Examiner Name	Julie Ha
Attorney Docket Number	101213-1P US

1	CARDUCCI, Michael A., et al. The Endothelin-A Receptor Antagonist Atrasentan (ABT-627) Delays Clinical Progression in Hormone Refractory Prostate Cancer: a Multinational, Randomized, Double-Blind, Placebo-Controlled Trial, Abstract from American Society for Clinical Oncology (ASCO), 2001 Annual Meeting.	<input type="checkbox"/>
2	CHIAO, JW, et al., Endothelin-1 from Prostate Cancer Cells is Enhanced by Bone Contact which Blocks Osteoclastic Bone Resorption, British Journal of Cancer, 2000, pp. 360-365, vol. 83(3).	<input type="checkbox"/>
3	CHIRGWIN, J.M., et al., Tumor-bone Cellular Interactions in Skeletal Metastases, J Musculoskel Neuron Interact 2004, pp. 308-318, vol. 4(3).	<input type="checkbox"/>
4	FIZAZI, Karim, The Effects of Endothelin-1 and Abt-627, an Endothelin-1 Antagonist, in an inVitro Model of Bone Metastases from Prostate Cancer, Abstract from American Society for Clinical Oncology (ASCO), 2001 Annual Meeting.	<input type="checkbox"/>
5	GUISE, Theresa, Endothelin A Receptor Blockade Inhibits Osteoblastic Metastases, Abstract from American Society for Clinical Oncology (ASCO), 2001 Annual Meeting.	<input type="checkbox"/>
6	JAMES, N.D., et al., ZD4054, A Potent, Specific Endothelin A Receptor Antagonist, Improves Overall Survival in Pain-Free or Mildly Symptomatic Patients with Hormone-Resistant Prostate Cancer (HRPC) and Bone Mestastases, European Journal of Cancer Supplements, 2007, p.3, vol. 5, no. 6.	<input type="checkbox"/>
7	NELSON, Joel B., et al., The Endothelin-A Receptor Antagonist Atrasentan (ABT-627) Reduces Skeletal Remodeling Activity in Men with Advanced, Hormone Refractory Prostate Cancer, Abstract from American Society for Clinical Oncology (ASCO), 2001 Annual Meeting.	<input type="checkbox"/>
8	VENUTI, Aldo et al., ABT 627: An Endothelin a Receptor Antagonist as New Antitumor Agent in HPV Associated Cervical Carcinoma, Abstract from American Society for Clinical Oncology (ASCO), 2001 Annual Meeting.	<input type="checkbox"/>
9	WARREN, Ruth, et al., ZD4054: A Specific Endothelin A Receptor Antagonist with Promising Activity in Metastatic Castration-Resistant Prostate Cancer, Expert Opinion, Investig. Drugs, 2008, pp. 1237-1245, vol. 17(8).	<input type="checkbox"/>
10	YUEN, K.K., Bisphosphonates for advanced prostate cancer (Review), The Cochrane Collaboration, The Cochrane Library, 2008, pp. 1-34, Issue 2.	<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button

Add

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
( Not for submission under 37 CFR 1.99)

Application Number	10569583
Filing Date	2006-02-23
First Named Inventor	Neil Gallagher
Art Unit	1654
Examiner Name	Julie Ha
Attorney Docket Number	101213-1P US

**EXAMINER SIGNATURE**

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> See Kind Codes of USPTO Patent Documents at [www.USPTO.GOV](http://www.USPTO.GOV) or MPEP 901.04. <sup>2</sup> Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>3</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>4</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>5</sup> Applicant is to place a check mark here if English language translation is attached.